Short answer
Corteva (CTVA) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2.5B (down 6.1% year over year) with net income of −$570M.
Q3 2026 key financials · XBRL
- Revenue
- $2.5B
- −6.1% YoY · −61.5% QoQ
- Net income
- −$570M
- −78.1% YoY · −149.1% QoQ
- EPS (diluted)
- −$0.84
- −82.6% YoY · −148.6% QoQ
Source: XBRL data from the Corteva (CTVA) Q3 2026 10-Q on SEC EDGAR. USD.
Corteva Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $2,458M, down 6% YoY from $2,618M, driven by volume down 6% and price down 2%
- COGS margin 62% vs 63% YoY, R&D 16% vs 13%, SG&A 30% vs 28%
- Best segment: Seed revenue $905M, down 1%; worst: Crop Protection revenue $1,553M, down 9%, EBITDA $213M vs $279M
- Cash $3,933M vs $4,530M at December 31; operating cash flow $(3,878)M vs $(941)M
- $860M returned to shareholders in nine months; near-term headwinds from Crop Protection pricing, Brazil conditions, higher IT and legal costs, and R&D investment
Risk Factors
- New regulatory risk: 2026 EPA, USDA, FDA and HHS funding and staff reductions could delay product approvals and re-registrations
- New antitrust risk: FTC and several states settled 2026 allegations concerning customer loyalty programs, potentially increasing regulatory scrutiny
- Environmental compliance risk: evolving PFAS and climate regulations could require costly facility modifications and create liabilities above accruals
- Supply-chain risk: material crop-protection inputs sourced directly or indirectly from China, increasing exposure to China-Taiwan conflict disruptions
- Financial risk: seasonal customer financing may require short-term debt, with access dependent on receivables and annual financing-program renewals
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corteva quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.